Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up

Inhibition of PCSK9 is a novel therapeutic strategy aimed at reducing low-density-lipoprotein cholesterol (LDL-C) and cardiovascular risk. Evolocumab is a fully humanized monoclonal antibody that inhibits PCSK9, an enzyme that binds to LDL receptors and prevents them from recycling to the hepatocyte...

Descripción completa

Detalles Bibliográficos
Autores principales: Dixon, Dave L, Buckley, Leo F, Trankle, Cory R, Kadariya, Dinesh, Abbate, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513834/
https://www.ncbi.nlm.nih.gov/pubmed/28744103
http://dx.doi.org/10.2147/DDDT.S114091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513834/
https://www.ncbi.nlm.nih.gov/pubmed/28744103
http://dx.doi.org/10.2147/DDDT.S114091

Ejemplares similares